MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ARAD, H.
Right arrow Articles by LEVITZKI, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ARAD, H.
Right arrow Articles by LEVITZKI, A.

Molecular Pharmacology, Vol 16, 749-756, Copyright © 1979 by the American Society for Pharmacology and Experimental Therapeutics

The Mechanism of Partial Agonism in the Beta-Receptor Dependent Adenylate Cyclase of Turkey Erythrocytes

HADAS ARAD 1 and ALEXANDER LEVITZKI 1

1 Department of Biological Chemistry, The Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel

The efficacy of nine different beta-agonists was measured, using three techniques in parallel: (a) the maximal steady state level of adenylate cyclase activity and (b) the first order rate constant describing the process of adenylate cyclase activation to its permanently active state, in the presence of GppNHp, and (c) the first order rate constant describing the process of cyclase deactivation, from its cAMP producing state to its inactive state. The efficacy of the beta-agonist as measured by the steady-state adenylate cyclase induced activity is directly proportional to the first order rate constant characterizing the activation of the enzyme by the agonist bound receptor. In contrast, the first order rate constant characterizing the deactivation of the adenylate cyclase from its cAMP producing state to its inactive state is independent of the agonist and of the absolute level of steady-state adenylate cyclase specific activity, which differs for each agonist. These results strongly suggest that the efficacy of a beta-agonist is solely dependent on the rate of adenylate cyclase activation by the agonist bound receptor.

Submitted on April 18, 1979
Accepted on July 2, 1979




This article has been cited by other articles:


Home page
ScienceHome page
A Levitzki
From epinephrine to cyclic AMP
Science, August 12, 1988; 241(4867): 800 - 806.
[Abstract] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1979 by the American Society for Pharmacology and Experimental Therapeutics